| Literature DB >> 35138427 |
Helen Brooks1, Angela Devereux-Fitzgerald2, Laura Richmond2, Penny Bee2, Karina Lovell2,3, Neil Caton4, Mary Gemma Cherry5,6, Bethan Mair Edwards4, James Downs4, Laura Bush7, Ivaylo Vassilev8, Bridget Young9, Anne Rogers8.
Abstract
BACKGROUND: Social connections have been linked to the genesis and amelioration of mental health problems and thus have potential therapeutic value.Entities:
Keywords: Mental health; Narrative synthesis; Social networks; Systematic review
Mesh:
Year: 2022 PMID: 35138427 PMCID: PMC9042995 DOI: 10.1007/s00127-022-02242-w
Source DB: PubMed Journal: Soc Psychiatry Psychiatr Epidemiol ISSN: 0933-7954 Impact factor: 4.519
Inclusion and exclusion criteria
| Inclusion criteria | Exclusion criteria |
|---|---|
| Published journal articles, or dissertations | Duplicate |
| Primary data from studies which are designed directly to improve the quantity or quality of social networks (based on whole network approach) | Not primary data (e.g. opinion pieces, review articles, book chapters) |
| AND | |
| Include a measure of social network size and/or quality as primary or secondary outcome | |
| Adults with primary diagnosis of mental health problems or self-attribution/non-medical labelling (e.g. stress or emotional distress) | Only available in abstract format |
| In mixed samples, mean age must be 18 or over and 75% of sample must have primary diagnosis of mental illness (self-report or physician defined) | |
| Controlled trials (CT) and randomised controlled trials (RCT) including cluster-randomised trials | Single case studies |
| Studies where primary diagnosis is substance misuse, autism, dementia, ADHD, cognitive impairment or spectrum disorders | |
| Patients without a primary diagnosis of mental health problems or self-attribution of mental difficulties (self-report or clinician diagnosis). In mixed samples 75% or more must have a primary diagnosis of mental illness or self-attribution of mental health difficulties | |
| Non-adult population: Mean age under 18 | |
| Pharmacological interventions | |
| Intervention’s primary function is not related to improving the quantity and/or quality of social networks (conceptualized as a whole network approach). The following will be excluded: | |
| 1. Dyadic interventions—couples, individual friendship interventions, family level only | |
| 2. Individual level intervention—e.g. intervention which aims to improve individual social skills, social functioning/dysfunctioning, social cognitions, confidence in social interaction, perceptions about social interaction, social interaction intentions | |
| No measure of social network quantity or quality | |
| Qualitative studies, feasibility studies or uncontrolled or unrandomised trials | |
| Not accessible |
Fig. 1PRISMA 2020 flow diagram
Overview of study quality, clinical significance and effect sizes for social network measures
| Study ref | Risk of bias | Intervention descriptor ( | Comparator descriptor ( | Outcome measure | Differences between groups—effect | Standardised effect size (or for dichotomous variables and effect size for continuous variables). longest follow-up |
|---|---|---|---|---|---|---|
| Terzian, 2013 | High | Supported social activity ( | Standard care ( | A social network improvement—defined as an increase in number, frequency, importance, or closeness of relationships | + | OR: 1.8. 95% CI: 1.2–2.9 |
| Sheridan, 2015 | High | Supported social activity, volunteer partner, stipend ( | Stipend only ( | Practitioner Assessment of Network Type | 0 | N/A |
| Social and Emotional Loneliness Scale for Adults | ||||||
| Rivera, 2007 | Unclear | Peer supported social activity ( | Standard case management ( | Pattison Network Inventory: Total number of social contacts | + | Compared to usual clinical care: Medium-effect size: 0.470497 |
| Usual clinical care ( | Social network size | 0 | ||||
| Density | 0 | |||||
| Reciprocity | 0 | |||||
| Castelein, 2008 | High | Closed peer support group (n = 56) | Waiting list control ( | Personal Network Questionnaire (PNQ) | + | Participants had a significant increase in contact with peers outside of the sessions. Not possible to calculate effect size |
The Social Support List (SSL) | + | Participants had a significant increase in esteem support (i.e. asked for advice, received a compliment, asked for help) Small effect size: 0.390877 | ||||
| Thorup, 2006 | High | Assertive community treatment ( | Standard care (n = 153) | Social network size | 0 | N/A |
| Tempier et al. 2012 | Unclear | Assertive community treatment ( | Standard care ( | Social network size | + | Medium-effect size: 0.609451 |
| Functional adequacy of social networks | 0 | N/A | ||||
| Calsyn, 1998 | Unclear | Assertive community treatment and community workers | Assertive community treatment | Network size: Size of professional network | + | No sample size provided |
| (sample sizes not provided for each condition) | Brokered condition (standard case management) | Size of natural network | 0 | N/A | ||
| Receipt of material assistance | + | No sample size provided | ||||
| Emotional, advice, recreational and conflict dimensions | 0 | N/A | ||||
Qualitative measures of social relationships Interviewer rated network support: | 0 | N/A | ||||
| Professional network | + | No sample size provided | ||||
| Natural network | 0 | N/A | ||||
| Johnson et al., 2018 | High | One-to-one recovery focussed intervention ( | Recovery workshop ( | Social network size | 0 | N/A |
| Los Angeles (UCLA) Loneliness Scale | 0 | N/A | ||||
| Ammerman, 2013 | Unclear | One-to-one cognitive behavioural therapy ( | Standard home visiting ( | Social Network Index—3 sub-scales: | 0 | N/A |
| Social network size | 0 | N/A | ||||
| Network diversity | 0 | N/A | ||||
| Embeddedness | + | Medium-effect size: 0.65 | ||||
| Interpersonal Support Evaluation List | + |
Overview of study quality, clinical significance and effect sizes for mental health outcomes
| Study refs | Risk of bias | Intervention descriptor ( | Comparator descriptor ( | Outcome measure | Differences between groups—effect | Standardised effect size (or for dichotomous variables and effect size for continuous variables). longest follow-up |
|---|---|---|---|---|---|---|
| Terzian et al., | High | Supported social activity ( | Standard care ( | Brief Psychiatric Rating Scale and Global Assessment of Functioning scores (a reduction of more than 3 points in the BPRS score or an increase of more than 5 in the GAF score were classified as clinical improvement) | 0 | N/A |
| Sheridan, 2015 | High | Supported social activity, volunteer partner, stipend ( | Stipend only ( | Beck’s Depression Inventory | 0 | N/A |
| Rivera, 2007 | Unclear | Peer supported social activity ( | Standard case management ( Usual clinical care ( | Service use Brief Symptom Inventory | 0 | N/A |
| Castelein, 2008 | High | Closed peer support group ( | Waiting list control ( | None included | N/A | N/A |
| Thorup, 2006 | High | Assertive community treatment ( | Standard care ( | None included | N/A | N/A |
| Tempier et al. 2012 | Unclear | Assertive community treatment ( | Standard care ( | Positive and Negative Syndrome Scale (PANSS) | + | Medium-effect size: 0.548072 |
| Social functioning was assessed by using the Global Assessment of Functioning (GAF) | + | Medium-effect size: 0.567348 | ||||
| Johnson et al., 2018 | High | One-to-one recovery focussed intervention ( | Recovery workshop ( | Readmission to an acute service | + | OR: 0·66 95% CI 0·43–0·99 |
| Days in acute care | 0 | |||||
Questionnaire on the Process of Recovery Illness | 0 | |||||
| Management and Recovery Scale | 0 | |||||
| Brief Psychiatric Rating Scale | 0 | |||||
| Ammerman, 2013 | Unclear | One-to-one cognitive behavioural therapy ( | Standard home visiting ( | Brief Symptom Inventory | + | Medium-effect size: 0.73 |
Overview of study quality, clinical significance and effect sizes for other outcomes
| Study refs | Risk of bias | Intervention descriptor ( | Comparator descriptor ( | Outcome measure | Differences between groups—effect | Standardised effect size (or for dichotomous variables and effect size for continuous variables). longest follow-up |
|---|---|---|---|---|---|---|
| Terzian et al., | High | Supported social activity ( | Standard care ( | Self-care | 0 | N/A |
| Activities of daily living | 0 | N/A | ||||
| Hospitalisations | 0 | N/A | ||||
| Sheridan, 2015 | High | Supported social activity, volunteer partner, stipend ( | Stipend only ( | Rosenberg’s Self-Esteem Scale | 0 | N/A |
| Rivera, 2007 | Unclear | Peer supported social activity ( | Standard case management ( | Behavioural Health Care Rating of Satisfaction | 0 | N/A |
| Usual clinical care ( | Lehman Quality of Life Inventory | 0 | N/A | |||
| Castelein, 2008 | HIGH | Closed peer support group ( | Waiting list control ( | Mental Health Confidence Scale (MHCS) | 0 | N/A |
| Rosenberg’s Self-Esteem Scale | 0 | N/A | ||||
| WHO Quality of Life (WHO QoL) Bref | 0 | N/A | ||||
| Thorup, 2006 | High | Assertive community treatment ( | Standard care ( | None reported | ||
| Tempier et al. 2012 | Unclear | Assertive community treatment ( | Standard care ( | None reported | ||
| Johnson et al., 2018 | High | One-to-one recovery focussed intervention ( | Recovery workshop ( | Client Satisfaction Questionnaire | 0 | N/A |
| Ammerman, 2013 | Unclear | One-to-one cognitive behavioural therapy ( | Standard home visiting ( | Not reported |
| Section and Topic | Item # | Checklist item | Location where item is reported |
|---|---|---|---|
| Title | 1 | Identify the report as a systematic review | Page 1 |
| Abstract | 2 | See the PRISMA 2020 for Abstracts checklist | Page 2 |
| Rationale | 3 | Describe the rationale for the review in the context of existing knowledge | Pages 3–4 |
| Objectives | 4 | Provide an explicit statement of the objective(s) or question(s) the review addresses | Pages 4–5 |
| Eligibility criteria | 5 | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses | Table |
| Information sources | 6 | Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted | Page 6 |
| Search strategy | 7 | Present the full search strategies for all databases, registers and websites, including any filters and limits used | Appendix 1 |
| Selection process | 8 | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process | Pages 6–7 |
| Data collection process | 9 | Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process | Pages 6–7 |
| Data items | 10a | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect | Pages 6–7 and Supplementary File 1 |
| 10b | List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information | Pages 6–7 and Supplementary File 1 | |
| Study risk-of-bias assessment | 11 | Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process | Page 8 and Supplementary File 1 |
| Effect measures | 12 | Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results | Page 8 and Table |
| Synthesis methods | 13a | Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)) | Page 7 |
| 13b | Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions | N/A | |
| 13c | Describe any methods used to tabulate or visually display results of individual studies and syntheses | Page 7 | |
| 13d | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used | Page 7 | |
| 13e | Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression) | N/A | |
| 13f | Describe any sensitivity analyses conducted to assess robustness of the synthesized results | N/A | |
| Reporting bias assessment | 14 | Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases) | Page 8 |
| Certainty assessment | 15 | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome | N/A |
| Study selection | 16a | Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram | Figure |
| 16b | Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded | Pages 5–6 and Table | |
| Study characteristics | 17 | Cite each included study and present its characteristics | Supplementary File 1 |
| Risk of bias in studies | 18 | Present assessments of risk of bias for each included study | Supplementary File 1 |
| Results of individual studies | 19 | For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots | Supplementary File 1 and Table |
| Results of syntheses | 20a | For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies | Page 8 |
| 20b | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect | N/A | |
| 20c | Present results of all investigations of possible causes of heterogeneity among study results | N/A | |
| 20d | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results | N/A | |
| Reporting biases | 21 | Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed | N/A |
| Certainty of evidence | 22 | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed | N/A |
| Discussion | 23a | Provide a general interpretation of the results in the context of other evidence | Pages 14–16 |
| 23b | Discuss any limitations of the evidence included in the review | Page 16 | |
| 23c | Discuss any limitations of the review processes used | Page 16 | |
| 23d | Discuss implications of the results for practice, policy, and future research | Pages 14–16 | |
| Registration and protocol | 24a | Provide registration information for the review, including register name and registration number, or state that the review was not registered | Page 5 |
| 24b | Indicate where the review protocol can be accessed, or state that a protocol was not prepared | Page 5 | |
| 24c | Describe and explain any amendments to information provided at registration or in the protocol | Page 5 | |
| Support | 25 | Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review | Page 17 |
| Competing interests | 26 | Declare any competing interests of review authors | Page 17 |
| Availability of data, code and other materials | 27 | Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review | Page 17 |
From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. https://doi.org/10.1136/bmj.n71
For more information ((see Fig. 1)